Michael Halstead - 18 Feb 2022 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
23 Feb 2022, 18:05:06 UTC
Prior SEC filing
11 Jan 2022
Next SEC filing
25 Feb 2022
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Lawrence J. Hineline, Attorney-in-fact

Key filing fact

Michael Halstead filed Form 4 for Intra-Cellular Therapies, Inc. (ITCI) on 23 Feb 2022.

Key facts

  • This page summarizes Michael Halstead's Form 4 filing for Intra-Cellular Therapies, Inc. (ITCI).
  • 4 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 23 Feb 2022, 18:05.

Change

  • Previous filing in this sequence was filed on 11 Jan 2022.
  • Current net transaction value: -$617,100.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ITCI transaction

Common Stock

Options Exercise

Transaction value
Shares
+11,139
Change %
Price
Shares after
11,139
Date
18 Feb 2022
Ownership
Direct
Footnotes
F1
ITCI transaction

Common Stock

Sale

Transaction value
$366,941
Shares
-6,589
Change %
-59%
Price
$55.69
Shares after
4,550
Date
22 Feb 2022
Ownership
Direct
Footnotes
F2, F3
ITCI transaction

Common Stock

Sale

Transaction value
$250,159
Shares
-4,550
Change %
-100%
Price
$54.98
Shares after
0
Date
22 Feb 2022
Ownership
Direct
Footnotes
F2, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ITCI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-11,139
Change %
-50%
Price
$0.000000
Shares after
11,139
Date
18 Feb 2022
Ownership
Direct
Underlying class
Common Stock
Underlying amount
11,139
Exercise price
Footnotes
F5, F6
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Restricted stock units convert into common stock on a one-for-one basis.

Footnote F2

This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2021. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.30 to $56.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F5

Each restricted stock unit represents a contingent right to receive one share of common stock.

Footnote F6

On February 18, 2020, the reporting person was granted 33,417 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .